ArticlemBio2026
A20 restricted PDCoV release through negative regulation of PANoptosis.
Article in mBio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronavirus infections can trigger multiple modes of cell death, leading to severe infectious diseases. The process is modulated by host factors with mechanisms yet to be fully elucidated. Here, we first demonstrated that the host factor A20 regulated PANoptosis during porcine deltacoronavirus (PDCoV) infection, thereby contributing to the antiviral defense response. We found that PDCoV could induce PANoptosis in intestinal epithelial cells, which facilitates the extracellular release of viral particles through this form of programmed cell death. A20 restricted the PANoptosome assembly and downstream death signaling by targeting RIPK3 ubiquitin chains for degradation. Consequently, loss of A20 exacerbated cell lysis and enhanced the release of viral particles, although this effect does not alter viral entry or replication. We further established that PDCoV-induced PANoptosis-dependent release was driven by osmotic imbalance resulting from membrane pore formation mediated by GSDMD and MLKL, rather than by direct transmembrane egress of viral particles. Transwell models showed that pharmacological inhibition of the pore-forming activities of GSDMD and MLKL reduced viral dissemination and preserved epithelial barrier integrity. These findings advance our understanding of enteric coronavirus pathogenesis and suggest that the A20-PANoptosis axis represents a potential target for antiviral intervention.IMPORTANCECoronaviruses have repeatedly posed significant threats to both human and animal health. Here, we used porcine deltacoronavirus (PDCoV), a highly enterotropic zoonotic pathogen, to uncover a novel mechanism by which coronaviruses exploit PANoptosis to facilitate viral egress. We demonstrate that PDCoV infection triggers PANoptosis in intestinal epithelial cells, leading to plasma membrane rupture and subsequent viral release. Importantly, we identified the host ubiquitin-editing enzyme A20 as a critical negative regulator of this process. A20 restricts PANoptosome assembly by specifically deubiquitinating RIPK3, thereby limiting cell lysis and suppressing viral dissemination without affecting viral replication. Our findings offer fundamental insights into coronavirus-host interactions and highlight the therapeutic potential of targeting lytic cell death to combat viral dissemination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.